TG Therapeutics, Inc. (TGTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in TG Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

TG Therapeutics, Inc. (TGTX) has returned 11.44% so far this year and -15.75% over the past 12 months. Looking at the last ten years, TGTX has achieved an annualized return of 14.00%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since May 3, 2010, TGTX's average daily return is +0.49%, while the average monthly return is +3.27%. At this rate, your investment would double in approximately 1.8 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jan 2012 with a return of +200.0%, while the worst month was Dec 2011 at -66.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, TGTX closed higher 44% of trading days. The best single day was Feb 6, 2012 with a return of +566.6%, while the worst single day was Jul 19, 2011 at -71.4%.

TG Therapeutics, Inc. has an annualized alpha of 180.55%, beta of 1.58, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 04, 2010.

• This stock participated in 198.56% of S&P 500 Index downside but only 115.30% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TGTX ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TG Therapeutics, Inc. was 99.52%, occurring on Dec 29, 2011. The portfolio has not yet recovered.

The current TG Therapeutics, Inc. drawdown is 85.77%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of TG Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how TG Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.